摘要
目的测定颅内支架术治疗前后患者C-反应蛋白(CRP)的水平,探讨阿托伐他汀对预防患者颅内支架再狭窄的可能性。方法将42例颅内支架患者随机分为对照组和治疗组(n=21)。对照组口服玻立维75mg+拜阿司匹林100mg,1次/d;治疗组口服阿托伐他汀40mg(术前7d开始)+玻立维75mg+拜阿司匹林100mg,1次/d。术前7d及1d,术后7d、3个月、6个月采用免疫透射比浊法分别测血清CRP水平。结果与对照组术前1d(7.44±0.73)mg/L、术后7d(27.61±1.81)mg/L、术后3个月(36.46±1.67)mg/L、术后6个月(26.84±0.76)mg/L比较,治疗组同期的CRP明显下降(P<0.05);与术后7d(12.05±0.55mg/L)比较,治疗组术前1d(6.22±0.57)mg/L、术后3个月(6.03±0.46)mg/L、6个月(6.12±0.77)mg/L下降明显(P<0.01);术前1d、术后3个月、6个月之间差异无统计学意义(P>0.05)。结论阿托伐他汀可有效抑制炎症因子,是预防支架内再狭窄的有效治疗方法之一。
Objective To investigate influence of C-reactive protein levele on pre-/post stent in intracranial artery treated with atorvastatin at the early stage. Method 42 patients treated with stent in intracranial artery were randomly divided into 2 groups: control group(n=21 ) receive plavix 75mg + aspirin enteric-coated tablet 100mg per day, treatment group(n=21) receive atorvastatin 40 mg(begining at day 7 pre-stenting) + plavix 75 mg + aspirin enteric-coated tablet 100mg per day. C-reactive protein level was examined at 7 d, and 1d before stenting and at 7d, 3 month, and 6 month after stenting with immunological transmission turbidimetry. Result Compared with control group C-reactive protein level at 1 day pre-stenting(7.44±0.73)mg/L, at 7 day post-stenting (27.61±1.81) mg/L, at 3 month post-stenting (36.46±1.67)mg/L, and at 6 month post-stenting (26.84±0.76)mg/L were significantly lower in treatment group(P〈0.05). Compared with the same period, C-reactive protein level was significantly higher in treatment group at 7 day post-stenting (12.05±0.55)mg/L. Compared with that in treatment group at 1 day prestenting(6.22±0.57)mg/L, at 3 month post-stenting(6.03±0.46)mg/L, and at 6 month post-stenting(6.12±0.77) mg/L,P〈0.01. There was no significant difference between day 1 pre-stenting, 3 month post-stenting,6 month poststenting(P〉0.05). Conclusion The therapy with atorvastatin turned out to be efficient to inhibit inflammatory factor and prevent stent restenosis.
出处
《热带医学杂志》
CAS
2010年第4期426-428,共3页
Journal of Tropical Medicine